Why Merrimack Pharmaceuticals Inc. Shares Plunged in After Hours

Merrimack shares take it on the chin after regaining full rights to its lead cancer drug and announcing additional phase 2 data.

Jun 19, 2014 at 7:50PM

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Merrimack Pharmaceuticals (NASDAQ:MACK), a biopharmaceutical company focused on developing therapies designed to treat cancer, dipped as much as 15% in after-hours trading after announcing an agreement with Sanofi (NYSE:SNY) to regain the worldwide rights to investigational cancer drug MM-121.

So what: According to its after-market press release, Merrimack appears positive after regaining development and worldwide commercialization rights to MM-121 which was tested in a series of phase 2 studies to assess the role of ErbB3 in a multitude of metastatic and neoadjuvant cancer settings. Per its press release, Sanofi will continue to fund existing phase 2 studies for the next six months.

In addition, Merrimack announced data from its second cohort of patients in its midstage collaboration of MM-121 in combination with paclitaxel in triple-negative breast cancer (TNBC) patients. According to its data release, the MM-121 intent to treat arm delivered a pCR rate of 42.9% compared to 51.7% for the control arm. In addition, adverse events were nearly double in the MM-121 arm relative to the control group (28.1% vs. 15.6%), so these results weren't very encouraging.

Now what: The real downside here is Sanofi walking away. By cutting its losses Sanofi walking could signify that there's little value in developing MM-121. More importantly, Merrimack is now down a very knowledgeable and experienced marketing partner and will soon be on the line for all additional MM-121 development costs.

There's also MM-121 itself, which showed no statistical benefit in a midstage treatment-resistant or refractory-advanced ovarian cancer study released in October. As a whole, the hazard ratio of 1 implied no clinical benefit, although it did identify some submarkers which could imply MM-121's future success on a more select group of cancer patients. Today's data from the TNBC cohort adds further fuel to the fire that MM-121 may not target a large enough audience to eventually be worthwhile for Merrimack or investors to stick around. It remains to be seen what Merrimack does moving forward, but as of now I'm sticking squarely on the sidelines.

Merrimack may offer plenty of potential, but keeping up with this top stock over the long haul might prove impossible!
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers